Prohibiting Abortion Industry’s Lucrative Loopholes Act

Bill Number

H.R. 727

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-01-24: Referred to the House Committee on Energy and Commerce.

Last Updated

2025-04-09T08:06:26Z

AI-Generated Summary

Purpose

This bill, titled the "Prohibiting Abortion Industry's Lucrative Loopholes Act," aims to strengthen existing federal restrictions on the sale or transfer of human fetal tissue (tissue from aborted fetuses) by expanding the definition of what counts as "valuable consideration" (any form of payment or benefit). The goal is to close potential loopholes that could allow indirect financial gains from such tissue, thereby prohibiting all profit-driven transactions.

Key Provisions

• Amends Section 498B(e) of the Public Health Service Act (a law governing public health research and protections).
• Replaces the existing paragraph (3) with a new definition of "valuable consideration," which now explicitly includes:
• Any payments made or debts incurred.
• Gifts, honorariums, or other recognitions of value.
• Waived, forgiven, reduced, or delayed fees, prices, or charges.
• Canceled or forgiven loans or debts.
• Free or reduced-cost transfers of items, services, or opportunities that are usually charged for.
• Payments related to the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.
• This expansion applies to prohibitions on buying, selling, or otherwise transferring human fetal tissue for valuable consideration, building on prior laws that already ban direct sales.

Significant Changes to Existing Law

• The original law (42 U.S.C. 289g-2) prohibited the sale of human fetal tissue for "valuable consideration" but left the term somewhat open to interpretation, potentially allowing indirect benefits like reimbursed costs or waived fees.
• This bill broadens the definition to cover a wider range of financial incentives or cost savings, effectively eliminating ambiguities and making enforcement stricter. It does not create new outright bans but reinforces and clarifies the existing prohibition.

Potential Impacts

• On government agencies: The Department of Health and Human Services (HHS) would likely see increased enforcement responsibilities, including oversight of research grants and investigations into tissue handling by federally funded entities. This could require additional resources for compliance monitoring.
• On citizens: May limit access to certain medical research derived from fetal tissue, such as studies on vaccines (e.g., for polio or COVID-19) or diseases like Parkinson's, potentially slowing advancements in treatments. It could also affect donations for research by making processes more regulated.
• On international relations: Minimal direct impact, though it might influence U.S. collaborations with foreign researchers or organizations involved in global health studies using fetal tissue, potentially complicating international medical partnerships.
• Overall, the bill could reduce the availability of fetal tissue for legitimate scientific purposes while aiming to deter any commercialization.

Main Stakeholders Affected

• Abortion providers and clinics: Directly impacted, as they may face stricter rules on handling and transferring fetal tissue post-procedure, potentially increasing operational costs or liabilities.
• Medical researchers and institutions: Universities, hospitals, and labs relying on fetal tissue for biomedical research (e.g., in regenerative medicine or immunology) could face funding cuts or delays if transactions involve any perceived "valuable consideration."
• Pharmaceutical companies: Those developing therapies or vaccines using fetal cell lines might encounter regulatory hurdles, affecting innovation timelines.
• Anti-abortion advocates: Likely supportive, as the bill aligns with efforts to restrict the abortion industry.
• Pro-research groups and patients: Could oppose it due to potential setbacks in medical progress benefiting public health.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens the 1993 ban on fetal tissue sales (part of the Public Health Service Act) by clarifying terms, which may lead to more successful prosecutions for violations. However, it could invite challenges over the vagueness of the expanded definition or enforcement burdens.
• Constitutional: No direct conflicts noted, but it might raise First Amendment concerns if applied to non-commercial discussions or donations, or Commerce Clause issues if it overly restricts interstate research activities. The bill focuses on federal protections without altering abortion rights established by cases like Roe v. Wade (overturned) or Dobbs v. Jackson.
• Political: Introduced by Republican representatives with a focus on anti-abortion priorities, it reflects ongoing debates over fetal tissue use in research. Passage could energize partisan divides in Congress, especially in committees like Energy and Commerce, but faces opposition from those prioritizing scientific freedom.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Franklin, Scott [R-FL-18]

Cosponsors (12)

Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Van Duyne, Beth [R-TX-24], Rep. Gosar, Paul A. [R-AZ-9], Rep. Self, Keith [R-TX-3], Rep. Rogers, Harold [R-KY-5], Rep. Ellzey, Jake [R-TX-6], Rep. Miller, Mary E. [R-IL-15], Rep. Babin, Brian [R-TX-36], Rep. Rutherford, John H. [R-FL-5], Rep. Webster, Daniel [R-FL-11], Rep. Moolenaar, John R. [R-MI-2], Rep. Biggs, Sheri [R-SC-3]

Recent Actions

• 2025-01-24: Referred to the House Committee on Energy and Commerce.
• 2025-01-24: Introduced in House
• 2025-01-24: Introduced in House

Bill Versions

• Prohibiting Abortion Industry’s Lucrative Loopholes Act — issued 2025-01-24 — PDF (2 pages)